Background: Doxycycline-based prevention of bacterial sexually transmitted infections (STIs) has been assessed in various studies and has been recommended by the European AIDS Clinical Society to be proposed to persons with repeated STIs on a case-by-case basis. However, while good preventive effects could be shown for Chlamydia trachomatis and Treponema pallidum in Europe, no reliable prevention against doxycycline resistance-affected bacterial causes of STIs like Neisseria gonorrhoeae and Mycoplasma genitalium was confirmed.
Methods: In a modelling-approach, we assessed potential beneficial effects even against the latter microorganisms in case of optimized adherence with doxycycline prevention. These effects were modelled for Germany in comparison to traditional prevention schemes like condom-based STI-prevention and testing-as-prevention.
Results: With estimated risk reduction in the ranges of 86% for N. gonorrhoeae and of 82% for Mycoplasma genitalium, expectable preventive efficacy similar to alternative preventive approaches could be calculated in case of optimized adherence with doxycycline prevention. In case of repeated risk exposure, the preventive potential of condom-based prevention was decreased compared to both optimized doxycycline prevention and testing-as-prevention.
Conclusions: As suggested by the applied modelling, the preventive effect of optimized doxycycline prevention against bacterial STIs is in a similar range, like other common prevention strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10895362 | PMC |
| http://dx.doi.org/10.1556/1886.2023.00059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DoxyPEP Implementation Preferences for Bacterial STD Prevention Among Gay, Bisexual, and Other Men Who Have Sex with Men Living With and Without HIV in Los Angeles: A Mixed-Methods Approach.
AIDS Patient Care STDS
January 2025
Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California, USA.
Bacterial sexually transmitted diseases (STDs) remain prominent in the United States among gay, bisexual, and other men who have sex with men (GBMSM). Doxycycline for post-exposure prophylaxis (DoxyPEP) is a regimen by which the antibiotic doxycycline is taken after sex to prevent bacterial STDs, such as, chlamydia, gonorrhea, and syphilis. Despite this, this study was conducted because there are a limited number of publications that describe GBMSM's knowledge of, and interest in, taking DoxyPEP and preferences regarding its implementation.
View Article and Find Full Text PDFDermatologic Adverse Events Following Afatinib in a Woman with Non-Small-Cell Lung Cancer: A Case Report.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran-Dr Hasan Sadikin Hospital, Bandung, West Java, Indonesia.
Epidermal growth factor receptor inhibitors (EGFRI) are biological factors used in several types of cancer, including non-small-cell lung cancers (NSCLC). One of the EGFR inhibitors that has been approved for NSCLC is afatinib. Dermatologic adverse events are the most commonly reported and may impair the patient's compliance to the therapy as it causes aesthetic discomfort and significantly impact the patient's quality of life.
View Article and Find Full Text PDFDoxycycline post-exposure prophylaxis (doxy-PEP) is a preventative strategy demonstrated to reduce bacterial sexually transmitted infections in high-risk populations. However, the impact of doxy-PEP on antibiotic resistance acquisition in key members of our microbiomes, is as of yet unclear. For example, commensal are known reservoirs of resistance for gonococci through horizontal gene transfer (HGT), and are more likely to experience bystander selection due to doxy-PEP as they are universally carried.
View Article and Find Full Text PDFDoxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention.
J Am Board Fam Med
January 2025
From the University of Tennessee College of Medicine Family Medicine Residency, Chattanooga, TN.
Consider prescribing doxycycline as prophylaxis for bacterial sexually transmitted infections (STIs) in certain clinical scenarios. New data suggests that a one-time dose of 200 mg doxycycline taken within 72 hours of an unprotected sexual encounter may reduce transmission of syphilis, gonorrhea and chlamydia by a combined two thirds in a high-risk population.
View Article and Find Full Text PDF[Dermatology. Doxy PEP and topical JAK inhibitors in inflammatory diseases].
Rev Med Suisse
January 2025
Service de dermatologie et vénéréologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
This article focuses on two key innovations in dermatology: post-exposure prophylaxis for sexually transmitted infections (STIs) and new therapeutic options for inflammatory skin diseases. New European and American guidelines for doxycycline post-exposure prophylaxis (Doxy PEP) aim to prevent STIs in men who have sex with men (MSM) and individuals on HIV pre-exposure prophylaxis (PrEP). Doxy PEP is effective against syphilis and chlamydia, but its efficacy is limited by growing gonorrhea resistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!